A global, retrospective, post-authorization study to characterize real-world effectiveness and safety of dostarlimab in patients with mismatch repair deficient (dMMR) or high microsatellite instability (MSI-H) recurrent or advanced endometrial cancer from racial and ethnic minority groups and in white patients.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.